Tramadol as a new probe for cytochrome P450 2D6 phenotyping: A population study

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 6, 2005, Pages 458-467

  Pedersen, Rasmus Steen ^a   Damkier, Per ^a   Brosen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; TRAMADOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; MOLECULAR PROBE; NAUSEA; NORMAL HUMAN; PHENOTYPE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; URINALYSIS;

ADULT; ANALGESICS, OPIOID; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; LIVER; MALE; OLIGONUCLEOTIDE PROBES; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; TRAMADOL;

EID: 20444477620     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.01.014     Document Type: Article

References (42)

1. A. Mahgoub, J.R. Idle, L.G. Dring, R. Lancaster, R.L. Smith Polymorphic hydroxylation of debrisoquine in man Lancet 2 1977 584 586
2. P. Dayer, R. Gasser, J. Gut, T. Kronbach, G.M. Robertz, M. Eichelbaum Characterization of a common genetic defect of cytochrome P-450 function (debrisoquinine-sparteine type polymorphism) Biomed Biophys Res Commun 125 1984 374 380
3. M. Schadel, D.A. Wu, S.V. Otton, W. Kalow, E.M. Sellers Pharmacokinetics of dextromethorphan and metabolites in humans influence of the CYP2D6 phenotype and quinidine inhibition J Clin Psychopharmacol 15 1995 263 269
4. M.S. Lennard, J.H. Silas, S. Freestone, L.E. Ramsay, G.T. Tucker, H.F. Woods Oxidation phenotype-a major determinant of metroprolol metabolism and response N Engl J Med 307 1982 1558 1560
5. M. Eichelbaum, N. Spannbrucker, B. Steinke, H.J. Dengler Defective N-oxidation of sparteine in man a new pharmacogenetic defect Eur J Clin Pharmacol 16 1979 183 187
6. A. Vinks, T. Inaba, S.V. Otton, W. Kalow Sparteine metabolism in Canadian Caucasians Clin Pharmacol Ther 31 1982 23 29
7. D.S. Streetman, J.S. Bertino, A.N. Nafziger Phenotyping of drug-metabolizing enzymes in adults a review of in-vivo cytochrome P450 phenotyping probes Pharmacogenetics 10 2000 187 216
8. T. Ebner, C.O. Meese, M. Eichelbaum Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans Mol Pharmacol 48 1995 1078 1086
9. E. Schaeffeler, M. Schwab, M. Eichelbaum, U.M. Zanger CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR Hum Mutat 22 2003 476 485
10. K. Brosen, S.V. Otton, L.F. Gram Sparteine oxidation polymorphism in Denmark Acta Pharmacol Toxicol 57 1985 357 360
11. E. Frankus, E. Friderichs, S.M. Kim, G. Osterloh On separation of isomeres, structural elucidation and pharmacological characterization of 1-(m-methoxyphenyl)-2-(dimethylaminomethyl)-cyclohexan-1-ol [in German] Arzneimittelforschung 28 1978 114 121
12. M.D. Vickers, D. Oflaherty, S.M. Szekely, M. Read, J. Yoshizumi Tramadol-pain relief by an opioid without depression of respiration Anaesthesia 47 1992 291 296
13. C.R. Lee, D. McTavish, E.M. Sorkim Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states Drugs 46 1993 313 340
14. T.A. Bamigbade, R.M. Langford The clinical use of tramadol hydrochloride Pain Rev 5 1998 155 182
15. R.B. Raffa, E. Friederichs, W. Reimann, R.P. Shank, E.E. Codd, J.L. Vaught Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an atypical opioid analgesic J Pharmacol Exp Ther 260 1992 275 285
16. M. Cossmann, C. Kohnen, R. Langford, C. McCartney Tolerability profile of tramadol findings from international studies and postmarketing surveillance data Drugs 53 1997 50 62
17. H. Jick, L.E. Derby, C. Vasilakis, D. Fife The risk of seizures associated with tramadol Pharmacotherapy 18 1998 607 611
18. T.P. Gibson Pharmacokinetics, efficacy and safety of analgesia with a focus on tramadol HCl Am J Med 101 1996 47S 53S
19. B.V.S. Murthy, K.S. Pandya, P.D. Booker, A. Murray, W. Lintz, R. Terlinden Pharmacokinetics of tramadol after i.v. or caudal epidural administration Br J Anaesth 84 2000 346 349
20. K.A. Payne, F. Fanzca, J.A. Roelofse Tramadol drops in children analgesic efficacy, lack of respiratory effects, and normal recovery times Anesth Prog 46 1999 91 96
21. O. Kaabachi, H. El Jaouani, H. Safi, Chakib Jelel, M. Ben Ghachem Comparative study of two protocols with tramadol for postoperative analgesia in children [in French] Tunis Med 80 2002 685 690
22. W.N. Wu, L.A. McKown, S. Liao Metabolism of the analgesic drug Ultram (tramadol hydrochloride) in humans API-MS and MS/MS characterization of metabolites Xenobiotica 32 2002 411 425
23. W. Lintz, S. Erlacin, E. Frankus, H. Uragg Biotransformation of tramadol in man and animal [in German] Arzneimittelforschung 31 1981 1932 1943
24. W.D. Paar, P. Frankus, H.J. Dengler The metabolism of tramadol by human liver microsomes Clin Investig 70 1992 708 710
25. V. Subrahmanyam, A.B. Renwick, D.G. Walters, P.J. Young, R.J. Price, A.P. Tonelli Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes Drug Metab Dispos 29 2001 1146 1155
26. W.D. Paar, S. Poche, J. Gerloff, H.J. Dengler Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol Eur J Pharmacol 53 1997 235 239
27. S.M. Abdel-Rahman, J.S. Leeder, J.T. Wilson, A. Gaedigk, R.R. Gotschall, R. Medve Concordance between tramadol and dextromethorphan parent/metabolite ratios the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation J Clin Pharmacol 42 2002 24 29
28. R.S. Pedersen, K. Brosen, F. Nielsen Enantioselective HPLC method for quantitative determination of tramadol and O-desmethyltramadol in plasma and urine application to clinical studies Chromatographia 57 2003 279 285
29. S. Laugesen, T.P. Enggaard, R.S. Pedersen, S.H. Sindrup, K. Brosen Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol Clin Pharmacol Ther 77 2005 312 323
30. M. Kagimoto, M. Heim, K. Kagimoto, T. Zeugin, U.A. Meyer Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes J Biol Chem 265 1990 17209 17214
31. D. Marez, M. Legrand, N. Sabbagh, J.M. LoGuidice, C. Spire, J.J. Lafitte Polymorphism of the cytochrome P450 CYP2D6 gene in a European population characterization of 48 mutations and 53 alleles, their frequencies and evolution Pharmacogenetics 7 1997 193 202
32. N. Hanioka, S. Kimura, U.A. Meyer, F.J. Gonzalez The human CYP2D locus associated with a common genetic defect in drug oxidation a G1934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site Am J Hum Genet 47 1990 994 1001
33. 450 CYP2D locus Nature 347 1990 773 776
34. B. Evert, E.U. Griese, M. Eichelbaum Cloning and sequencing of a new non-functional CYP2D6 allele deletion of T1795 in exon 3 generates a premature stop codon Pharmacogenetics 4 1994 271 274
35. A.K. Daly, J.B. Leathart, S.J. London, J.R. Idle An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution Hum Genet 95 1995 337 341
36. R. Saxena, G.L. Shaw, M.W. Relling, J.N. Frame, D.T. Moir, W.E. Evans Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype Hum Mol Genet 3 1994 923 926
37. R. Tyndale, T. Aoyama, F. Broly, T. Matsunaga, T. Inaba, W. Kalow Identification of a new variant CYP2D6 allele lacking the codon encoding LYS-281 possible association with the poor metabolizer phenotype Pharmacogenetics 1 1991 26 32
38. F. Broly, U.A. Meyer Debrisoquine oxidation polymorphism phenotypic consequence of a 3-base-pair deletion in exon 5 of the CYP2D6 gene Pharmacogenetics 3 1993 123 130
39. G. Alvan, P. Bechtel, L. Iselius, U. Gundertremy Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations Eur J Clin Pharmacol 39 1990 533 537
40. L. Poulsen, L. Arendt-Nielsen, K. Brosen, S.H. Sindrup The hypoalgesic effect of tramadol in relation to CYP2D6 Clin Pharmacol Ther 60 1996 636 644
41. A. Gaedigk, M. Blum, R. Gaedigk, M. Eichelbaum, U.A. Meyer Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug-metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism Am J Hum Genet 48 1991 943 950
42. L.D. Bradford CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 3 2002 229 243